Novo Nordisk and Anthropic announced a collaboration to test Anthropic’s Claude Science across drug development R&D workflows, aiming to accelerate discovery and development. The companies say they will identify high-impact research challenges and use frontier models to support software engineering and broader AI scaling. The deal follows Novo’s earlier AI partnership work and reflects intensifying competition among pharma companies to embed large-model capabilities into discovery, data processing, and operational software layers. For biotech readers focused on execution, the key near-term detail is the planned workflow-specific pilot rather than a full-platform migration—an approach that can reduce adoption risk while validating measurable productivity gains.